• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $AFIB

    Acutus Medical Inc.

    Subscribe to $AFIB
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Acutus Medical, Inc., an arrhythmia management company, designs, manufactures, and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. Its product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact force ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. Acutus Medical, Inc. was incorporated in 2011 and is based in Carlsbad, California.

    IPO Year: 2020

    Exchange: NASDAQ

    Website: acutusmedical.com

    Recent Analyst Ratings for Acutus Medical Inc.

    DatePrice TargetRatingAnalyst
    1/20/2022Buy → Neutral
    BTIG
    1/14/2022$10.00 → $3.00Buy → Hold
    Canaccord Genuity
    11/15/2021Neutral → Underweight
    JP Morgan
    11/12/2021Neutral → Underweight
    JP Morgan
    11/12/2021$18.00 → $10.00Buy
    Canaccord Genuity
    10/22/2021$10.00Neutral
    Goldman
    7/15/2021$11.00 → $18.00Hold → Buy
    Canaccord Genuity
    See more ratings

    Acutus Medical Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Acutus Medical Reports Full Year 2024 Financial Results

      CARLSBAD, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (OTC:AFIB) today reported results for the full year of 2024. Recent Highlights: 2024 Revenue from Continuing Operations of $20.2 million grew 181% year-over-year, from $7.2 million last year.Operating loss for continuing operations was $0.1 million, compared to 11.7 million last year.Recorded $10.8 million in gain on sale of business, an increase of 19% compared to last year.Cash, cash equivalents, marketable securities and restricted cash were $14.0 million as of December 31, 2024. Full Year 2024 Financial ResultsRevenue from Continuing Operations was $20.2 million for 2024, an increas

      3/24/25 4:01:00 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Acutus Medical Announces Operational Downsizing

      CARLSBAD, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (NASDAQ:AFIB), today announced a realignment of resources and operational downsizing. Dr. Shaden Marzouk, Chairperson of the Board of Directors of Acutus, commented, "Following an extensive strategic review by the Company's Board of Directors, we are taking the hard but necessary steps to reduce the size of our organization while complying with our remaining obligations to Medtronic for the production of left-heart access products." Takeo Mukai, CEO & CFO of Acutus, added, "The operational downsizing impacts our team, and it is difficult to part with our valued and highly talented colleag

      12/4/24 4:01:00 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Acutus Medical Reports Third Quarter and Year-To-Date 2024 Financial Results

      CARLSBAD, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (OTC:AFIB) today reported results for the third quarter and year-to-date of 2024. Recent Highlights: Third quarter revenue from Continuing Operations of $5.3 million grew 156% year-over-year, from $2.1 million in the same quarter last year.Operating income for continuing operations was $0.1 million, an improvement of 119% compared to the same period last year.Recorded $2.4 million in gain on sale of business, a decrease of 8% compared to the same period last year.Cash, cash equivalents, marketable securities and restricted cash were $12.6 million as of September 30, 2024. Thi

      11/14/24 4:26:42 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Acutus Medical Reports Second Quarter and Year-To-Date 2024 Financial Results

      CARLSBAD, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (OTC:AFIB) today reported results for the second quarter and year-to-date of 2024. Recent Highlights: Second quarter revenue from Continuing Operations of $4.1 million grew 172% year-over-year, from $1.5 million in the same quarter last year.Operating expenses for continuing operations were $2.2 million, a reduction of 47% compared to the same period last year.Recorded $2.9 million in gain on sale of business, an increase of 38% compared to the same period last year.Cash, cash equivalents, marketable securities and restricted cash were $13.3 million as of June 30, 2024. Second Quarter 20

      8/8/24 4:56:33 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Acutus Medical Reports First Quarter 2024 Financial Results

      CARLSBAD, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (OTC:AFIB) today reported results for the first quarter of 2024. Recent Highlights: First quarter revenue from Continuing Operations of $3.6 million grew 192% year-over-year, from $1.2 million in the same quarter last year..Operating expenses for continuing operations were $3.3 million, a reduction of 38% compared to the same period last year.Recorded $2.8 million in gain on sale of business, an increase of 131% compared to the same period last year.Cash, cash equivalents, marketable securities and restricted cash were $20.0 million as of March 31, 2024. First Quarter 2024 Financial

      5/9/24 4:01:00 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Acutus Medical Reports Fourth Quarter and Full Year 2023 Financial Results

      CARLSBAD, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (NASDAQ:AFIB) today reported results for the fourth quarter and full year ended December 31,2023. Recent Highlights: Announced strategic realignment of resources and corporate restructuring on November 8, 2023 with the objective of optimizing financial position and maximizing free cash flow.The Continuing Operations focuses on the implementation of the business model to shift to solely support the manufacturing and distribution of Medtronic's left-heart access product portfolio.Discontinued Operations relates to the Company's mapping and ablation business that was wound down as part of t

      4/1/24 4:05:00 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Acutus Medical to Cancel Third Quarter 2023 Conference Call

      CARLSBAD, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (NASDAQ:AFIB), today announced that, following the Company's announcement of its strategic realignment of resources and corporate restructuring and release of its third quarter results on November 8, 2023, the Company will no longer hold its third quarter results conference call and webcast which was previously scheduled for Monday, November 13, 2023. About Acutus Medical, Inc.Acutus is focused on the production of left-heart access products under its distribution agreement with Medtronic, Inc. Founded in 2011, Acutus is based in Carlsbad, California. Investor Contact:Chad HollisterAcutus

      11/10/23 4:01:00 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Acutus Medical Reports Third Quarter 2023 Financial Results

      CARLSBAD, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (NASDAQ:AFIB) today reported results for the third quarter of 2023. Recent Highlights: Third quarter revenue of $5.2 million grew 44% year-over-year, led by strong growth in distribution revenue from sales of left-heart access products to MedtronicRegistered significant year-over-year reductions in both GAAP and non-GAAP operating expenses and cash burn, resulting from disciplined focus on expense managementAnnounced strategic realignment of resources and corporate restructuring with the objective of optimizing financial position and maximizing free cash flow Third Quarter 2023 Financial

      11/8/23 4:01:00 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Acutus Medical Announces Strategic Realignment of Resources and Corporate Restructuring

      CARLSBAD, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (NASDAQ:AFIB), today announced a realignment of resources and corporate restructuring. Scott Huennekens, Chairman of Acutus, commented, "Following an extensive strategic review by the Company's Board of Directors, we are taking the hard but necessary steps to streamline our operations. In light of the current financing environment and the capital investments required to achieve leadership in the electrophysiology (EP) market, we have concluded that the optimal use of the Company's resources is to reallocate capital from our mapping and ablation business to the manufacturing of left-heart a

      11/8/23 4:00:00 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Acutus Medical to Announce Third Quarter 2023 Financial Results

      CARLSBAD, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus") (NASDAQ:AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that it will release its third quarter 2023 financial results on Monday, November 13, 2023. In conjunction with the release, Acutus will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. To access the live call via telephone, please register in advance using the link here. Upon registering, each participant will receive an email confirmation with dial-in numbers and a

      11/2/23 4:13:07 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    Acutus Medical Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director by deputization Flynn James E

      4 - Acutus Medical, Inc. (0001522860) (Issuer)

      1/28/25 9:00:08 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Mukai Takeo covered exercise/tax liability with 8,475 units of Form 4, decreasing direct ownership by 10% to 72,874 units (SEC Form 4)

      4 - Acutus Medical, Inc. (0001522860) (Issuer)

      3/4/24 5:20:05 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Sohn Tom covered exercise/tax liability with 7,582 units of Form 4, decreasing direct ownership by 7% to 105,009 units (SEC Form 4)

      4 - Acutus Medical, Inc. (0001522860) (Issuer)

      2/7/24 4:12:59 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Mukai Takeo covered exercise/tax liability with 2,869 units of Form 4, decreasing direct ownership by 3% to 81,349 units (SEC Form 4)

      4 - Acutus Medical, Inc. (0001522860) (Issuer)

      2/2/24 4:06:56 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Sohn Tom covered exercise/tax liability with 5,709 units of Form 4, decreasing direct ownership by 5% to 112,591 units (SEC Form 4)

      4 - Acutus Medical, Inc. (0001522860) (Issuer)

      2/2/24 4:05:00 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Mathews Kevin covered exercise/tax liability with 6,342 units of Form 4, decreasing direct ownership by 9% to 61,106 units (SEC Form 4)

      4 - Acutus Medical, Inc. (0001522860) (Issuer)

      1/18/24 4:10:53 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Roman David covered exercise/tax liability with 24,086 units of Form 4, decreasing direct ownership by 7% to 332,134 units (SEC Form 4)

      4 - Acutus Medical, Inc. (0001522860) (Issuer)

      1/18/24 4:10:04 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4: Mukai Takeo covered exercise/tax liability with 1,729 units of FORM 4, decreasing direct ownership by 2% to 84,218 units

      4 - Acutus Medical, Inc. (0001522860) (Issuer)

      9/5/23 4:24:43 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4: Sohn Tom covered exercise/tax liability with 433 units of FORM 4, decreasing direct ownership by 0.36% to 118,300 units

      4 - Acutus Medical, Inc. (0001522860) (Issuer)

      8/7/23 5:50:32 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4: Mathews Kevin covered exercise/tax liability with 134 units of FORM 4, decreasing direct ownership by 0.20% to 67,448 units

      4 - Acutus Medical, Inc. (0001522860) (Issuer)

      8/7/23 5:50:14 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    Acutus Medical Inc. SEC Filings

    See more
    • SEC Form 10-K filed by Acutus Medical Inc.

      10-K - Acutus Medical, Inc. (0001522860) (Filer)

      3/24/25 5:27:27 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Acutus Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Acutus Medical, Inc. (0001522860) (Filer)

      3/24/25 4:07:31 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Acutus Medical Inc.

      SCHEDULE 13D/A - Acutus Medical, Inc. (0001522860) (Subject)

      1/28/25 5:40:03 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 15-15D filed by Acutus Medical Inc.

      15-15D - Acutus Medical, Inc. (0001522860) (Filer)

      1/24/25 5:16:39 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form EFFECT filed by Acutus Medical Inc.

      EFFECT - Acutus Medical, Inc. (0001522860) (Filer)

      1/24/25 12:15:04 AM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form EFFECT filed by Acutus Medical Inc.

      EFFECT - Acutus Medical, Inc. (0001522860) (Filer)

      1/24/25 12:15:05 AM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Acutus Medical Inc.

      SCHEDULE 13D/A - Acutus Medical, Inc. (0001522860) (Subject)

      1/23/25 9:16:26 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form S-8 POS filed by Acutus Medical Inc.

      S-8 POS - Acutus Medical, Inc. (0001522860) (Filer)

      1/21/25 4:27:02 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form S-8 POS filed by Acutus Medical Inc.

      S-8 POS - Acutus Medical, Inc. (0001522860) (Filer)

      1/21/25 4:25:06 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form S-8 POS filed by Acutus Medical Inc.

      S-8 POS - Acutus Medical, Inc. (0001522860) (Filer)

      1/21/25 4:23:01 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    Acutus Medical Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Acutus Medical Inc.

      SC 13D/A - Acutus Medical, Inc. (0001522860) (Subject)

      12/16/24 9:52:56 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Acutus Medical Inc.

      SC 13G/A - Acutus Medical, Inc. (0001522860) (Subject)

      11/14/24 1:03:20 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by Acutus Medical Inc.

      SC 13G - Acutus Medical, Inc. (0001522860) (Subject)

      5/17/24 5:20:26 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13D/A filed by Acutus Medical Inc. (Amendment)

      SC 13D/A - Acutus Medical, Inc. (0001522860) (Subject)

      11/13/23 4:46:40 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Acutus Medical Inc. (Amendment)

      SC 13G/A - Acutus Medical, Inc. (0001522860) (Subject)

      2/13/23 2:49:27 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13D/A filed by Acutus Medical Inc. (Amendment)

      SC 13D/A - Acutus Medical, Inc. (0001522860) (Subject)

      7/5/22 5:15:57 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13D/A filed by Acutus Medical Inc. (Amendment)

      SC 13D/A - Acutus Medical, Inc. (0001522860) (Subject)

      4/27/22 3:49:59 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by Acutus Medical Inc.

      SC 13G - Acutus Medical, Inc. (0001522860) (Subject)

      2/11/22 2:48:42 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13D/A filed by Acutus Medical, Inc. (Amendment)

      SC 13D/A - Acutus Medical, Inc. (0001522860) (Subject)

      11/18/21 4:56:22 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13D/A filed by Acutus Medical, Inc. (Amendment)

      SC 13D/A - Acutus Medical, Inc. (0001522860) (Subject)

      8/31/21 4:52:15 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    Acutus Medical Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Acutus Medical downgraded by BTIG

      BTIG downgraded Acutus Medical from Buy to Neutral

      1/20/22 9:29:42 AM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Acutus Medical downgraded by Canaccord Genuity with a new price target

      Canaccord Genuity downgraded Acutus Medical from Buy to Hold and set a new price target of $3.00 from $10.00 previously

      1/14/22 8:31:41 AM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Acutus Medical downgraded by JP Morgan

      JP Morgan downgraded Acutus Medical from Neutral to Underweight

      11/15/21 7:17:46 AM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Acutus Medical downgraded by JP Morgan

      JP Morgan downgraded Acutus Medical from Neutral to Underweight

      11/12/21 9:22:19 AM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Canaccord Genuity reiterated coverage on Acutus Medical with a new price target

      Canaccord Genuity reiterated coverage of Acutus Medical with a rating of Buy and set a new price target of $10.00 from $18.00 previously

      11/12/21 8:48:42 AM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Goldman initiated coverage on Acutus Medical with a new price target

      Goldman initiated coverage of Acutus Medical with a rating of Neutral and set a new price target of $10.00

      10/22/21 7:09:25 AM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Acutus Medical upgraded by Canaccord Genuity with a new price target

      Canaccord Genuity upgraded Acutus Medical from Hold to Buy and set a new price target of $18.00 from $11.00 previously

      7/15/21 7:15:04 AM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Canaccord Genuity reiterated coverage on Acutus Medical with a new price target

      Canaccord Genuity reiterated coverage of Acutus Medical with a rating of Hold and set a new price target of $16.00 from $30.00 previously

      3/19/21 11:59:20 AM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Acutus Medical downgraded by William Blair

      William Blair downgraded Acutus Medical from Outperform to Market Perform

      3/19/21 8:27:43 AM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Acutus Medical downgraded by William Blair with a new price target

      William Blair downgraded Acutus Medical from Outperform to Mkt Perform and set a new price target of $19.00 from $39.00 previously

      3/19/21 8:02:50 AM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    Acutus Medical Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Acutus Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Results and Appointment of Chief Financial Officer

      CARLSBAD, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (NASDAQ:AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced preliminary unaudited results for the fourth quarter and full year 2022. The Company also announced the appointment of Takeo Mukai as Senior Vice President & Chief Financial Officer. Preliminary Unaudited Fourth Quarter and Full Year 2022 ResultsThe Company expects fourth quarter 2022 revenue of approximately $4.7-$4.9 million compared to $4.4 million in the fourth quarter of 2021. Year-over-year growth was driven by an increase in commercial AcQMap pr

      1/9/23 6:00:00 AM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BrightInsight Adds Medical Device and Biopharmaceutical Experts, Tamara Elias, M.D., and Scott Huennekens to Advisory Council

      SAN JOSE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- BrightInsight, Inc., provider of the leading global platform for biopharma and medtech regulated digital health solutions, announced today the appointment of Tamara Elias, M.D., Senior Vice President at Nuance, and Scott Huennekens, executive chairperson at Hyperfine, Wondr Medical, Acutus Medical and Envista Holdings Corporation, to the BrightInsight Advisory Council. Dr. Elias and Huennekens bring deep and complimentary experience to this group of industry experts, who work with BrightInsight leadership to advance the company's vision to transform patient outcomes globally through the power of digital technology. Dr. Elias and Huennek

      9/7/22 8:30:00 AM ET
      $AFIB
      $AVGR
      $HYPR
      $NUVA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
      Medical/Dental Instruments
    • Acutus Medical Appoints Niamh Pellegrini to Board of Directors

      CARLSBAD, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Acutus Medical ("Acutus") (NASDAQ:AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced the appointment of Niamh Pellegrini to the Company's Board of Directors, effective August 10, 2021. Ms. Pellegrini has over 20 years of experience in the healthcare industry and, since July 2019, has served as the Chief Commercial Officer of Nevro, Inc., a medical device company dedicated to helping patients suffering from chronic pain achieve lasting relief. "Niamh is an experienced and proven executive and commercial leader," said Vince Burgess, President and CEO of Acutu

      8/12/21 4:02:00 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Acutus Medical Board Appoints John Sheridan as a New Director

      CARLSBAD, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- Acutus Medical (Nasdaq: AFIB) today announced the appointment of John Sheridan to the Company's Board of Directors effective March 17, 2021. Since March 2019, Mr. Sheridan has been the President and Chief Executive Officer of Tandem Diabetes Care, Inc., a medical device company specializing in the design, development and commercialization of products for people with insulin-dependent diabetes. He has been a member of Tandem’s Board of Directors since June 2019 and a member of the executive management team since 2013. "John has an accomplished track record of growing medical device companies while consistently creating value for all sta

      3/18/21 6:00:00 AM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Acutus Medical Appoints Duane Wilder as Chief Commercial Officer

      CARLSBAD, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Acutus Medical (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced the appointment of Duane Wilder as the company’s Chief Commercial Officer. Mr. Wilder joins Acutus with over 25 years of commercial experience in the medical technology industry. Most recently, Mr. Wilder served as Vice President of US Sales, for the Image Guided Therapy division of Philips, where he had National responsibility for all of Philips’ Image Guided Therapy equipment and service sales, as well as the disposable catheters used with the equipment. Previously, Mr. Wilder held

      3/2/21 8:00:00 AM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    Acutus Medical Inc. Financials

    Live finance-specific insights

    See more
    • Acutus Medical to Cancel Third Quarter 2023 Conference Call

      CARLSBAD, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (NASDAQ:AFIB), today announced that, following the Company's announcement of its strategic realignment of resources and corporate restructuring and release of its third quarter results on November 8, 2023, the Company will no longer hold its third quarter results conference call and webcast which was previously scheduled for Monday, November 13, 2023. About Acutus Medical, Inc.Acutus is focused on the production of left-heart access products under its distribution agreement with Medtronic, Inc. Founded in 2011, Acutus is based in Carlsbad, California. Investor Contact:Chad HollisterAcutus

      11/10/23 4:01:00 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Acutus Medical to Announce Third Quarter 2023 Financial Results

      CARLSBAD, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus") (NASDAQ:AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that it will release its third quarter 2023 financial results on Monday, November 13, 2023. In conjunction with the release, Acutus will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. To access the live call via telephone, please register in advance using the link here. Upon registering, each participant will receive an email confirmation with dial-in numbers and a

      11/2/23 4:13:07 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Acutus Medical Reports Second Quarter 2023 Financial Results

      CARLSBAD, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (NASDAQ:AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the second quarter of 2023. Recent Highlights: Second quarter revenue of $5.3 million grew 30% year-over-year, reflecting strong procedure volume growth and improved capital salesQuarterly AcQMap procedure volumes set a new record and increased 21% compared to the second quarter of 2022Received FDA 510K clearance for AcQMap 9 next generation software platform featuring advanced algorithms and automation to improve diagnostic capabil

      8/7/23 4:01:00 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Acutus Medical to Announce Second Quarter 2023 Financial Results

      CARLSBAD, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus") (NASDAQ:AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that it will release its second quarter 2023 financial results on Monday, August 7, 2023. In conjunction with the release, Acutus will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. To access the live call via telephone, please register in advance using the link here. Upon registering, each participant will receive an email confirmation with dial-in numbers and a uni

      7/24/23 4:01:00 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Acutus Medical Reports First Quarter 2023 Financial Results

      CARLSBAD, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (NASDAQ:AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the first quarter of 2023. Recent Highlights: Reported revenue of $4.2 million for the first quarter of 2023, a 13% increase compared to $3.7 million for the same quarter last year.Continued improvement in financial performance with year-over-year reductions of 58% in GAAP operating expenses, and year-over-year reductions of 39% in both non-GAAP operating expenses and cash burn for the first quarter of 2023.Increased full year revenue outloo

      5/11/23 4:01:00 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Acutus Medical to Announce First Quarter 2023 Financial Results

      CARLSBAD, Calif., April 28, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus") (NASDAQ:AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that it will release its first quarter 2023 financial results on Thursday, May 11, 2023. In conjunction with the release, Acutus will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. To access the live call via telephone, please register in advance using the link here. Upon registering, each participant will receive an email confirmation with dial-in numbers and a uni

      4/28/23 5:15:00 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • RECOVER AF Study Reports 91% of First Redo Patients Achieved Freedom from AF at One Year After AcQMap-guided Ablation Therapy

      CARLSBAD, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus") (NASDAQ:AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced results from the RECOVER AF study. The study, published online in EP Europace, found that patients who received AcQMap-guided ablations for retreatment achieved better outcomes compared to those who underwent traditional anatomical retreatment strategies.1-3 Moreover, the study showed patients who had only undergone pulmonary vein isolation (PVI) before enrollment achieved 91% freedom from atrial fibrillation (AF) at one year, while the entire study population, with v

      4/20/23 8:00:00 AM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Acutus Medical Reports Fourth Quarter and Full Year 2022 Financial Results

      CARLSBAD, Calif., March 16, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (NASDAQ:AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the fourth quarter and full year ended December 31, 2022. Financial statements and other information presented for 2022 is unaudited. Recent Highlights: Reported revenue of $5.0 million for the fourth quarter of 2022, a 14% increase compared to $4.4 million for the same quarter last yearReported revenue of $16.4 million for the full year of 2022, a 5% decrease compared to $17.3 million for the full year of 2021Global mapping procedure volu

      3/16/23 4:01:00 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Acutus Medical to Announce Fourth Quarter and Full Year 2022 Financial Results

      CARLSBAD, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus") (NASDAQ:AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that it will release its fourth quarter and full year 2022 financial results on Thursday, March 16, 2023. In conjunction with the release, Acutus will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. To access the live call via telephone, please register in advance using the link here. Upon registering, each participant will receive an email confirmation with dial-i

      3/9/23 4:01:00 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Acutus Medical Reports Third Quarter 2022 Financial Results

      CARLSBAD, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (NASDAQ:AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the third quarter of 2022. Recent Updates: Reported revenue of $3.6 million in the third quarter of 2022, compared to $4.6 million in the same quarter last yearGlobal mapping procedures volumes increased 17% from the same quarter last yearGenerated significant year-over-year reductions in operating expenses and cash burn for the third quarter of 2022Submitted US premarket approval (PMA) application for the AcQBlate Force-Sensing Ablation Ca

      11/10/22 4:01:00 PM ET
      $AFIB
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care